AG真人官方

Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences (CSTL), reported the sale of 12,677 shares of the company's common stock in a transaction executed at a weighted-average price of $22.019 per share. The reported sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and, after the transaction, the reporting person beneficially owned 141,116 shares. The filing discloses that the sale occurred in multiple trades at prices ranging from $22.000 to $22.145 and that the reporting person will provide detailed trade-level information on request.

Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences, Inc. (CSTL), reported the sale of 18,007 shares of the issuer's common stock on 08/27/2025. The sales were executed in multiple trades at prices ranging from $21.24 to $21.94, with a reported weighted-average sale price of $21.69. Following the reported disposition, Oelschlager beneficially owned 153,793 shares, held directly. The Form 4 was signed by an attorney-in-fact, Frank Stokes, on 08/29/2025. The filer affirms availability to provide trade-level price and share details upon request.

Form 144 filing for Castle Biosciences, Inc. (CSTL) shows a proposed Rule 144 sale of 18,007 shares of common stock through J.P. Morgan Securities LLC on 08/27/2025 on NASDAQ with an aggregate market value of $384,449.45. The shares stem from restricted stock units granted by the issuer: 10,171 RSUs acquired 03/04/2025 and 7,836 RSUs acquired 08/08/2025, with payment characterized as compensation. No sales by the reporting person in the past three months are reported. The filer attests there is no undisclosed material adverse information.

Castle Biosciences (CSTL) submitted a Form 144 disclosing a proposed sale of 25,355 shares of common stock through J.P. Morgan Securities LLC on or about 08/27/2025 on the NASDAQ. The filing reports an aggregate market value of $541,329 against 29,008,281 shares outstanding. The shares originated from two Restricted Stock Unit grants received as compensation: 7,837 units acquired on 08/09/2024 and 17,518 units acquired on 12/09/2024, with payment/vesting dates matching acquisition dates. The filer certifies no undisclosed material adverse information and indicates this is a LIVE filing.

Castle Biosciences director and CEO Derek J. Maetzold reported a sale of 1,339 shares of Castle Biosciences common stock executed under a Rule 10b5-1 plan at a weighted-average price of $20.04 per share. The filing states the sale was executed in multiple trades with prices ranging from $20.00 to $20.10 and that the reporting person will provide trade-level details upon request.

Following the reported transaction, the form discloses the reporting persons remaining direct and indirect beneficial ownership across trusts and vehicles, including 68,344 shares held directly and multiple indirect holdings (for example, 52,923, 44,986, 85,959, and others) held through family and grantor retained annuity trusts. The sale was made pursuant to a pre-established written plan adopted in May 2025.

Filing type: Rule 144 notice for proposed sale of securities by an affiliate of Castle Biosciences (CSTL).

The filer plans to sell 4,017 shares of common stock through Goldman Sachs & Co. LLC on 08/15/2025, with an aggregate market value of $80,701.53. The company reports 29,008,281 shares outstanding. The shares to be sold were acquired on 08/09/2024 as performance awards and were paid as compensation.

The filing also discloses multiple prior sales by related persons in the past three months, including transactions on 06/27/2025 (several sellers totaling multiple thousands of shares with gross proceeds listed) and a larger sale by Derek Maetzold of 43,019 shares on 08/13/2025 for $836,452.83. The notice includes the filers certification regarding absence of undisclosed material adverse information.

Derek J. Maetzold, President, CEO and Director of Castle Biosciences (CSTL), reported an insider sale under a Rule 10b5-1 plan. On 08/13/2025 he disposed of 43,019 shares of Castle common stock in multiple trades at a weighted-average sale price of $19.504 per share, reducing his direct holdings to 69,683 shares. The filing lists multiple indirect holdings across trusts (largest indirect positions: 85,959; 52,923; 44,986; 44,323; 18,718 shares) that remain held by various family and grantor retained annuity trusts. The 10b5-1 plan was adopted on November 11, 2024. The form is a routine Section 16 disclosure of an executed sale plan.

Castle Biosciences (CSTL) disclosed a proposed sale of 43,019 common shares through Goldman Sachs & Co. LLC with an aggregate market value of $834,998.79. The form lists the approximate date of sale as 08/13/2025 and identifies the securities exchange as NASD. The shares were recorded as acquired on 08/08/2025 from the issuer as performance award compensation, with payment dated 08/08/2025. The filing also reports multiple related-party sales on 06/27/2025 by The Maetzold trusts and Derek Maetzold totaling specific share amounts and gross proceeds. The filer certifies compliance with Rule 144 and affirms no undisclosed material adverse information.

Derek Maetzold, President & CEO and a director of Castle Biosciences (CSTL), reported the conversion of 66,991 performance-based stock units into common shares and a sale of 23,972 shares at $19.36 on 08/08/2025. After the reported sale his direct beneficial ownership is shown as 112,702 shares. The filing documents trust movements on July 11, 2025 (transfers into his direct holdings) and July 14, 2025 (transfer of 44,323 shares from his direct holdings to a grantor retained annuity trust). The PSUs converted represent the remaining 50% of a December 23, 2022 grant that vested in full on the one-year anniversary of August 9, 2024.